Cell Therapy Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Therapy Type (Autologous, Allogenic), By Therapeutic Area (Oncology, Cardiovascular Diseases, Musculoskeletal Disorders, Dermatology), By Region, By Competition, 2028

Industry : Healthcare
Pages : NA
Published Date : NA

Customization Enquiry

Buy Now

Single User Licence

$4500

Multi-User Licence

$5500

Custom Research Licence

$8000

Summary

Request Sample

Report Description

Forecast Period	2024-2028
Market Size (2022)	USD 5.02 Billion
CAGR (2023-2028)	12.09%
Fastest Growing Segment	Oncology
Largest Market	North America

Market Overview

Global Cell Therapy Market has valued at USD 5.02 billion in 2022 and is anticipated to project formidable growth in the forecast period with a CAGR of 12.09% through 2028. In the realm of modern medicine, the convergence of science and innovation has given rise to transformative treatments that were once considered science fiction. One such groundbreaking advancement is cell therapy, a cutting-edge medical approach that harnesses the power of living cells to treat a range of diseases and conditions. The global cell therapy market is rapidly expanding, offering new hope for patients and creating a paradigm shift in the way healthcare is delivered. Cell therapy involves the transplantation or manipulation of living cells into a patient's body to stimulate the repair, regeneration, or replacement of damaged or diseased tissues. These cells can be sourced from the patient's own body (autologous) or from a donor (allogeneic). The therapeutic potential of cell therapy lies in its ability to target the root causes of various diseases at a cellular level, unlike traditional treatments that often focus on symptom management. The global cell therapy market has gained substantial momentum in recent years due to its promising outcomes and a growing understanding of cellular biology. The market encompasses various therapeutic areas, including oncology, cardiovascular diseases, neurological disorders, musculoskeletal conditions, and autoimmune disorders. Cancer treatment, in particular, has seen significant advancements with the development of chimeric antigen receptor (CAR) T-cell therapies that reprogram the patient's immune cells to target and destroy cancer cells. The market is also supported by increased investment from pharmaceutical companies, research institutions, and venture capital firms. Governments around the world are recognizing the potential of cell therapy and are providing regulatory support, streamlined approval processes, and funding to expedite its development and commercialization. Despite the challenges, the global cell therapy market is poised for substantial growth. Ongoing research into cellular biology, advances in gene editing techniques (such as CRISPR-Cas9), and innovative approaches to manufacturing are expected to drive progress. The convergence of cell therapy with other fields like genomics and artificial intelligence holds the potential to further refine treatment approaches, making them even more personalized and effective. Moreover, the expansion of the market beyond traditional applications to areas like wound healing, diabetes, and rare genetic disorders could unlock new avenues for growth. As the body of evidence supporting the efficacy of cell therapies continues to grow, more stakeholders, including healthcare providers, insurers, and patients, are likely to embrace these treatments as a viable option.

Key Market Drivers

Growing Prevalence of Chronic and Genetic Diseases is driving the Global Cell Therapy Market

In recent years, there has been a significant increase in the prevalence of chronic and genetic diseases worldwide. This surge in disease burden has spurred the growth of innovative medical solutions, among which cell therapy has emerged as a promising avenue for treatment. Cell therapy involves the transplantation or introduction of cells into a patient's body to restore or improve their physiological functions, making it a groundbreaking approach in the field of regenerative medicine. The global cell therapy market is now experiencing remarkable expansion, primarily fueled by the urgent need to address the rising incidence of chronic and genetic diseases. Chronic diseases, such as cardiovascular diseases, diabetes, cancer, and neurodegenerative disorders, are now the leading causes of death and disability worldwide. These conditions place an immense burden on healthcare systems and individuals alike, leading to increased healthcare costs, decreased quality of life, and substantial societal and economic challenges. Additionally, genetic diseases, which are caused by abnormalities in an individual's DNA, can have debilitating effects from birth or manifest later in life, further contributing to the overall disease burden. Cell therapy presents a novel approach to tackling these complex diseases by harnessing the body's own regenerative potential. It involves the transplantation of healthy cells, often derived from the patient's own body or from donors, to replace damaged or dysfunctional cells. This can range from stem cell-based therapies that aim to regenerate damaged tissues, to immunotherapies that enhance the body's immune response against cancer cells. The versatility and potential of cell therapy to target a wide array of diseases has ignited a wave of research and development in this field.

Increasing Patient Demand for Personalized Medicine is Driving the Global Cell Therapy Market

Traditional medical approaches often followed a one-size-fits-all model, where treatments were developed based on generalized guidelines and the average patient's response. However, this approach did not always yield optimal results, as individuals can respond differently to the same treatment due to genetic variations and other factors. This led to the realization that a more individualized approach to medicine could lead to better outcomes and improved patient experiences. Personalized medicine, backed by advancements in genomics, molecular biology, and data analytics, has enabled healthcare providers to target treatments to the specific characteristics of each patient. This approach has gained immense popularity not only among medical professionals but also among patients who are seeking more effective and tailored solutions for their health conditions. Cell therapy, a branch of regenerative medicine, has emerged as a promising avenue for personalized treatments. It involves using living cells to replace or repair damaged tissue and restore normal function. This approach is particularly relevant for conditions that cannot be adequately treated with traditional medications or surgical interventions. Cell therapy offers the advantage of customization, as cells can be sourced from the patient's own body (autologous) or from carefully matched donors (allogeneic). This eliminates the risk of immune rejection and reduces adverse effects, making cell therapy a safer and more effective option for many patients. The patient-centric nature of personalized medicine has played a pivotal role in driving the global cell therapy market. Patients are increasingly seeking treatments that address their unique medical needs, and cell therapy aligns perfectly with this demand. Patients are drawn to cell therapy's potential for more effective and lasting outcomes. Witnessing success stories of individuals who have experienced remarkable recoveries through cell-based treatments has fueled patient interest and demand. Traditional treatments often come with a range of side effects that can impact a patient's quality of life. Cell therapy's ability to minimize adverse effects and enhance overall well-being has piqued patient curiosity. The proliferation of information through the internet and social media has led to increased awareness about cutting-edge medical treatments. Patients are now more informed and proactive in exploring innovative therapies that can address their specific health issues.

Download Free Sample Report

Key Market Challenges

Complex Regulatory Landscape

One of the foremost challenges in the cell therapy market is navigating the complex and evolving regulatory landscape. Unlike traditional pharmaceuticals, which are based on small molecules, cell therapies involve live cells that interact with the patient's body. This dynamic nature raises unique safety and efficacy concerns, leading to intricate regulatory requirements. Ensuring compliance with these regulations can be time-consuming and resource-intensive, potentially delaying the development and approval process.

Safety and Efficacy Concerns

Cell therapies often involve modifying or transplanting cells into patients, which can introduce unforeseen risks. Ensuring the safety of patients is paramount, as unintended side effects or complications could have serious consequences. Additionally, demonstrating the efficacy of cell therapies requires rigorous clinical trials and long-term follow-up, which can be logistically challenging and resource-intensive.

Standardization and Scalability

Manufacturing cell therapies at scale while maintaining consistent quality is a significant hurdle. Unlike traditional drugs, which can be mass-produced with relative ease, cell therapies involve working with living cells that are sensitive to environmental conditions. Developing standardized manufacturing processes and techniques that can be reliably replicated is essential to ensure consistent outcomes for patients.

Cost and Reimbursement

Cell therapies are often associated with high development and manufacturing costs, partly due to the complexities of working with living cells and complying with rigorous regulations. The high costs can present challenges in terms of affordability for patients and reimbursement by healthcare systems. Striking a balance between making these therapies accessible to those in need while ensuring the sustainability of the industry is a delicate task.

Lack of Understanding and Awareness

The concept of cell therapy is still relatively new to the general public and even some medical professionals. This lack of awareness and understanding can hinder the adoption and acceptance of these treatments. Education efforts are needed to inform both patients and healthcare providers about the potential benefits and risks of cell therapies, enabling more informed decision-making.

Key Market Trends

Technological Advancements

The field of medical science is undergoing a transformative phase, with remarkable breakthroughs occurring at an unprecedented pace. Among these groundbreaking advancements, cell therapy stands out as a beacon of hope, promising revolutionary treatments for a multitude of diseases that were once considered untreatable. As technological innovations continue to accelerate, the cell therapy market is experiencing a rapid expansion, offering new avenues for treating a diverse range of medical conditions. Stem cells, with their unique ability to differentiate into various cell types, have captured the attention of researchers and clinicians alike. Advances in stem cell isolation, manipulation, and differentiation techniques have enabled the development of personalized therapies for conditions ranging from neurodegenerative disorders to cardiovascular diseases. The emergence of precise gene editing tools like CRISPR-Cas9 has revolutionized the field of cell therapy. This technology allows scientists to modify a cell's genetic material, correcting mutations or enhancing desired traits before transplantation. Gene-edited cells offer improved therapeutic potential and reduced risks of immune rejection. Immunotherapies harness the body's immune system to target and destroy disease-causing cells. Chimeric Antigen Receptor (CAR) T-cell therapy, a form of immunotherapy, has shown remarkable success in treating certain types of leukemia and lymphoma. Ongoing research aims to expand the applications of CAR-T therapy to solid tumors and other diseases. Microfluidic devices and automated systems have streamlined the production and manipulation of cells for therapy. These technologies enhance scalability, consistency, and quality control, ensuring that cell-based treatments can be manufactured in large quantities without compromising safety and efficacy. As technology continues to evolve, the cell therapy market is projected to experience exponential growth. The convergence of these technological advancements has propelled the development of novel and effective therapies for conditions that were once considered incurable. From autoimmune diseases to degenerative disorders, the spectrum of diseases that can potentially be addressed through cell therapy continues to expand. However, it's important to note that along with the potential benefits, challenges remain. Safety concerns, regulatory hurdles, and the complexities of manufacturing consistent and viable cell therapies on a large scale are among the issues that need to be addressed to fully realize the potential of this field.

Segmental Insights

Therapy Type Insights

In 2022, the Cell Therapy market was dominated by the Autologous Therapy segment and is predicted to continue expanding over the coming years. Autologous therapy refers to a type of cell therapy where a patient's own cells are collected, processed, and then reintroduced back into the patient's body to treat a specific condition. Autologous therapy eliminates the risk of immune rejection since the cells being used are sourced from the patient's own body. This addresses one of the major challenges in cell therapy, as allogeneic therapies (using cells from another donor) can lead to immune system rejection, requiring the use of immunosuppressive drugs.

Therapeutic Area Insights

In 2022, the Cell Therapy market was dominated by the Oncology segment and is predicted to continue expanding over the coming years. Cancer is a complex and often challenging disease to treat. Traditional treatment methods like chemotherapy, radiation therapy, and surgery have limitations, and there is a constant need for more effective and targeted therapies. Cell therapies, especially those involving immune cells like CAR-T cells (chimeric antigen receptor T cells), have shown promising results in treating certain types of cancer that are resistant to other treatments. Immunotherapy, which includes cell therapies like CAR-T cell therapy, harnesses the body's immune system to recognize and attack cancer cells. This approach has transformed cancer treatment by providing potentially curative options for patients who had limited or no treatment options previously. CAR-T cell therapies, for instance, involve modifying a patient's T cells to recognize and target cancer cells, leading to improved outcomes in certain leukemia and lymphoma cases.

Download Free Sample Report

Regional Insights

North America, particularly the United States, has a long history of investing in biomedical research and innovation. This has led to the development of advanced technologies and methodologies for cell therapy, including stem cell research and regenerative medicine. North America boasts a robust biotechnology and pharmaceutical industry, with numerous established companies and startups focusing on cell therapy research and development. These companies often have the financial resources and expertise to advance their products to the market. Regulatory agencies in North America, such as the U.S. Food and Drug Administration (FDA), have provided clear pathways for the approval and commercialization of cell therapies. This clarity has encouraged companies to invest in research and development in the region. North America also has a well-developed healthcare infrastructure, including a vast network of hospitals and research institutions. This infrastructure supports the clinical trials and testing necessary for the approval and adoption of new cell therapies.

Recent Developments

In August 2023, Artiva Biotherapeutics has received approval from the FDA for their Investigational New Drug (IND) application for AlloNK® (also referred to as AB-101). This approval allows for the use of AlloNK in combination with rituximab to treat patients with active lupus nephritis (LN), a component of systemic lupus erythematosus (SLE). AlloNK is an experimental NK cell therapy derived from cord blood that has not been genetically modified. It is designed to boost antibody-dependent cellular cytotoxicity (ADCC). This achievement marks the first time an off-the-shelf NK or CAR-T cell therapy has been granted IND clearance for an autoimmune disease.
In August 2023, Astellas Pharma and Poseida Therapeutics revealed a strategic investment, aimed at providing additional backing for the advancement of cancer cell therapies.
In June 2023, the FDA granted approval to Bristol Myers Squibb for its recently inaugurated advanced cell therapy manufacturing plant in Devens, Massachusetts. This expansion is projected to bolster BMS' worldwide cell therapy production capacity and sustain the ongoing availability of its cell therapy items in the long run.
In April 2023, Bristol Myers Squibb and Novartis joined forces to enhance their expertise in cell therapy. They established a U.S. manufacturing facility dedicated to producing viral vectors for CAR T cell therapies.

Key Market Players

Novartis AG
Gilead Sciences, Inc.
Bristol-Myers Squibb Company
Johnson & Johnson Services, Inc
JCR Pharmaceuticals Co., Ltd.
Tego Science
Atara Biotherapeutics
Takeda Pharmaceutical Company Limited
Bluebird Bio, Inc.
Dendreon Corp.

By Therapy Type	By Therapeutic Area	By Region
Autologous Allogenic	Oncology Cardiovascular Diseases Musculoskeletal Disorders Dermatology	North America Asia-Pacific Europe Middle East & Africa South America

Report Scope:

In this report, the Global Cell Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cell Therapy Market, By Therapy Type:

o Autologous

o Allogenic

Cell Therapy Market, By Therapeutic Area:

o Oncology

o Cardiovascular Diseases

o Musculoskeletal Disorders

o Dermatology

Cell Therapy Market, By Region:

o North America

o Asia-Pacific

o Europe

o Middle East & Africa

o South America

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cell Therapy Market.

Available Customizations:

Global Cell Therapy Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Middle East & Africa Cell Therapy Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1. Product Overview

1.1. Market Definition

1.2. Scope of the Market

1.2.1. Markets Covered

1.2.2. Years Considered for Study

1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study

2.2. Baseline Methodology

2.3. Key Industry Partners

2.4. Major Association and Secondary Sources

2.5. Forecasting Methodology

2.6. Data Triangulation & Validations

2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market

3.2. Overview of Key Market Segmentations

3.3. Overview of Key Market Players

3.4. Overview of Key Regions/Countries

3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cell Therapy Market Outlook

5.1. Market Size & Forecast

5.1.1. By Value

5.2. Market Share & Forecast

5.2.1. By Therapy Type (Autologous, Allogenic)

5.2.2. By Therapeutic Area (Oncology, Cardiovascular Diseases, Musculoskeletal Disorders, Dermatology)

5.2.3. By Region

5.2.4. By Company (Shares of Top 5 Market Players)

5.3. Market Map

5.3.1. By Therapy Type

5.3.2. By Therapeutic Area

5.3.3. By Region

6. North America Cell Therapy Market Outlook

6.1. Market Size & Forecast

6.1.1. By Value

6.2. Market Share & Forecast

6.2.1. By Therapy Type

6.2.2. By Therapeutic Area

6.2.3. By Country

6.2.3.1. United States Cell Therapy Market Outlook

6.2.3.1.1. Market Size & Forecast

6.2.3.1.1.1. By Value

6.2.3.1.2. Market Share & Forecast

6.2.3.1.2.1. By Therapy Type

6.2.3.1.2.2. By Therapeutic Area

6.2.3.2. Canada Cell Therapy Market Outlook

6.2.3.2.1. Market Size & Forecast

6.2.3.2.1.1. By Value

6.2.3.2.2. Market Share & Forecast

6.2.3.2.2.1. By Therapy Type

6.2.3.2.2.2. By Therapeutic Area

6.2.3.3. Mexico Cell Therapy Market Outlook

6.2.3.3.1. Market Size & Forecast

6.2.3.3.1.1. By Value

6.2.3.3.2. Market Share & Forecast

6.2.3.3.2.1. By Test

6.2.3.3.2.2. By Therapeutic Area

7. Europe Cell Therapy Market Outlook

7.1. Market Size & Forecast

7.1.1. By Value

7.2. Market Share & Forecast

7.2.1. By Therapy Type

7.2.2. By Therapeutic Area

7.2.3. By Country

7.2.4.1. France Cell Therapy Market Outlook

7.2.4.1.1. Market Size & Forecast

7.2.4.1.1.1. By Value

7.2.4.1.2. Market Share & Forecast

7.2.4.1.2.1. By Therapy Type

7.2.4.1.2.2. By Therapeutic Area

7.2.4.2. Germany Cell Therapy Market Outlook

7.2.4.2.1. Market Size & Forecast

7.2.4.2.1.1. By Value

7.2.4.2.2. Market Share & Forecast

7.2.4.2.2.1. By Therapy Type

7.2.4.2.2.2. By Therapeutic Area

7.2.4.3. United Kingdom Cell Therapy Market Outlook

7.2.4.3.1. Market Size & Forecast

7.2.4.3.1.1. By Value

7.2.4.3.2. Market Share & Forecast

7.2.4.3.2.1. By Therapy Type

7.2.4.3.2.2. By Therapeutic Area

7.2.4.4. Italy Cell Therapy Market Outlook

7.2.4.4.1. Market Size & Forecast

7.2.4.4.1.1. By Value

7.2.4.4.2. Market Share & Forecast

7.2.4.4.2.1. By Therapy Type

7.2.4.4.2.2. By Therapeutic Area

7.2.4.5. Spain Cell Therapy Market Outlook

7.2.4.5.1. Market Size & Forecast

7.2.4.5.1.1. By Value

7.2.4.5.2. Market Share & Forecast

7.2.4.5.2.1. By Therapy Type

7.2.4.5.2.2. By Therapeutic Area

8. Asia Pacific Cell Therapy Market Outlook

8.1. Market Size & Forecast

8.1.1. By Value

8.2. Market Share & Forecast

8.2.1. By Therapy Type

8.2.2. By Therapeutic Area

8.2.3. By Country

8.2.3.1. China Cell Therapy Market Outlook

8.2.3.1.1. Market Size & Forecast

8.2.3.1.1.1. By Value

8.2.3.1.2. Market Share & Forecast

8.2.3.1.2.1. By Therapy Type

8.2.3.1.2.2. By Therapeutic Area

8.2.3.2. India Cell Therapy Market Outlook

8.2.3.2.1. Market Size & Forecast

8.2.3.2.1.1. By Value

8.2.3.2.2. Market Share & Forecast

8.2.3.2.2.1. By Therapy Type

8.2.3.2.2.2. By Therapeutic Area

8.2.3.3. South Korea Cell Therapy Market Outlook

8.2.3.3.1. Market Size & Forecast

8.2.3.3.1.1. By Value

8.2.3.3.2. Market Share & Forecast

8.2.3.3.2.1. By Therapy Type

8.2.3.3.2.2. By Therapeutic Area

8.2.3.4. Japan Cell Therapy Market Outlook

8.2.3.4.1. Market Size & Forecast

8.2.3.4.1.1. By Value

8.2.3.4.2. Market Share & Forecast

8.2.3.4.2.1. By Therapy Type

8.2.3.4.2.2. By Therapeutic Area

8.2.3.5. Australia Cell Therapy Market Outlook

8.2.3.5.1. Market Size & Forecast

8.2.3.5.1.1. By Value

8.2.3.5.2. Market Share & Forecast

8.2.3.5.2.1. By Therapy Type

8.2.3.5.2.2. By Therapeutic Area

9. South America Cell Therapy Market Outlook

9.1. Market Size & Forecast

9.1.1. By Value

9.2. Market Share & Forecast

9.2.1. By Type

9.2.2. By Therapeutic Area

9.2.3. By Country

9.2.3.1. Brazil Cell Therapy Market Outlook

9.2.3.1.1. Market Size & Forecast

9.2.3.1.1.1. By Value

9.2.3.1.2. Market Share & Forecast

9.2.3.1.2.1. By Therapy Type

9.2.3.1.2.2. By Therapeutic Area

9.2.3.2. Argentina Cell Therapy Market Outlook

9.2.3.2.1. Market Size & Forecast

9.2.3.2.1.1. By Value

9.2.3.2.2. Market Share & Forecast

9.2.3.2.2.1. By Therapy Type

9.2.3.2.2.2. By Therapeutic Area

9.2.3.3. Colombia Cell Therapy Market Outlook

9.2.3.3.1. Market Size & Forecast

9.2.3.3.1.1. By Value

9.2.3.3.2. Market Share & Forecast

9.2.3.3.2.1. By Therapy Type

9.2.3.3.2.2. By Therapeutic Area

10. Middle East & Africa Cell Therapy Market Outlook

10.1. Market Size & Forecast

10.1.1. By Value

10.2. Market Share & Forecast

10.2.1. By Type

10.2.2. By Therapeutic Area

10.2.3. By Country

10.2.3.1. South Africa Cell Therapy Market Outlook

10.2.3.1.1. Market Size & Forecast

10.2.3.1.1.1. By Value

10.2.3.1.2. Market Share & Forecast

10.2.3.1.2.1. By Therapy Type

10.2.3.1.2.2. By Therapeutic Area

10.2.3.2. Saudi Arabia Cell Therapy Market Outlook

10.2.3.2.1. Market Size & Forecast

10.2.3.2.1.1. By Value

10.2.3.2.2. Market Share & Forecast

10.2.3.2.2.1. By Therapy Type

10.2.3.2.2.2. By Therapeutic Area

10.2.3.3. UAE Cell Therapy Market Outlook

10.2.3.3.1. Market Size & Forecast

10.2.3.3.1.1. By Value

10.2.3.3.2. Market Share & Forecast

10.2.3.3.2.1. By Therapy Type

10.2.3.3.2.2. By Therapeutic Area

11. Market Dynamics

11.1. Drivers

11.2. Challenges

12. Market Trends & Developments

12.1. Recent Development

12.2. Mergers & Acquisitions

12.3. Therapy Type Launches

13. Competitive Landscape

13.1. Novartis AG

13.2. Gilead Sciences, Inc.

13.3. Bristol-Myers Squibb Company

13.4. Johnson & Johnson Services, Inc

13.5. JCR Pharmaceuticals Co., Ltd.

13.6. Tego Science

13.7. Atara Biotherapeutics

13.8. Takeda Pharmaceutical Company Limited

13.9. Bluebird Bio, Inc.

13.10. Dendreon Corp.

14. Strategic Recommendations

About us & Disclaimer

Figures and Tables

Frequently asked questions

What was the market size of the Global Cell Therapy Market in 2022?

The market size of the Global Cell Therapy Market was estimated to be USD 5.02 billion in 2022.

Who are the top players operating in the Middle East & Africa Cell Therapy Market in 2022?

Novartis AG, Gilead Sciences, Inc., Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc, JCR Pharmaceuticals Co., Ltd., Tego Science, Atara Biotherapeutics, Takeda Pharmaceutical Company Limited, Bluebird Bio, Inc., Dendreon Corp. are some of the key players operating in the Global Cell Therapy Market.

Which is the dominant region in the Global Cell Therapy Market?

North America has dominated the growth of Global Cell Therapy Market in the forecast period. North America has been a leader in medical research and clinical trials for decades. This leadership extends to cell therapy research, which has allowed the region to maintain a competitive edge in the global market.

What are the major drivers for the Middle East & Africa Cell Therapy Market?

Rising prevalence of chronic and genetic diseases and increasing patient demand for personalized medicine are the major drivers for the Global Cell Therapy Market.

Related Reports

Sakshi Bajaal

Business Consultant

Talk To Analyst

Press Release

Cell Therapy Market to Grow with a CAGR of 12.09% Through 2028

Oct, 2023

Rising Prevalence of Chronic and Genetic Diseases and Increasing Patient Demand for Personalized Medicine are driving Global Cell Therapy Market in the forecast period 2024-2028.